B+
Bull case
25%
Probability
Target price
$118.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
GMED
Globus MedicalANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The Q2 print supports a constructive view: organic growth excluding Nevro, spine share gains, gross-margin expansion, operating leverage, and a higher EPS outlook suggest earnings conversion may improve through FY2026. The supplied median analyst target of $103.23 is about 32% above the $78.12 anchor, but target-count data is unavailable.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +20.7.
What can break
A director completed a 25,000-share open-market sale after exercising options; insider activity should not be treated as an operating signal. [#SEC-FORM4-2026-08-19]
Momentum
29
Value
65
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $103.23 · Bull $118.00 · Bear $67.00Analysis 2026-09-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $103.23
Why
Momentum29 · Δ7d -1.7
Value65 · Δ7d -0.0
Sentiment100 · Δ7d +20.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +20.7.
Contradictions & invalidation
- • A director completed a 25,000-share open-market sale after exercising options; insider activity should not be treated as an operating signal. [#SEC-FORM4-2026-08-19]
- • GAAP EPS declined year over year because of the prior-year Nevro bargain-purchase gain, which may complicate headline comparisons. [#SEC-8K-2026-08-06]
- • The company still faces integration and execution risk around Nevro, relatively modest reported Q2 growth, and uncertainty over whether above-market spine growth and margin gains persist.
Catalyst clock
2026-08-06
Q2 2026 earnings and raised EPS outlook
Lead driver: Sentiment · See AI snapshot
Momentum
29
9% active weight
Current posture
7d trendImproving
Δ7d
-1.7
Δ21d
-19.0
Value
65
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+3.0
Sentiment
100
62% active weight
Current posture
7d trendImproving
Δ7d
+20.7
Δ21d
+25.6
Why this grade
Composite grade A. Momentum 29.3 / Value 65.3 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-04. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$103.23
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$67.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$11.43B
Beta
1.06
Shares Out
134.26M
P/E (TTM)
29.2
P/S (TTM)
4.37
P/FCF (TTM)
21.25
Rev YoY
+5.9%
EPS YoY
-25.8%
Gross Margin
+64.9%
Op Margin
+21.5%
Net Debt
-$437.8M
Current Ratio
4.62
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data